Martinez-Martin Pablo, Schrag Anette, Weintraub Daniel, Rizos Alexandra, Rodriguez-Blazquez Carmen, Chaudhuri Kallol Ray
National Center of Epidemiology and CIBERNED Carlos III Institute of Health Madrid Spain.
Department of Clinical Neurosciences, Royal Free Campus Institute of Neurology University College London London United Kingdom.
Mov Disord Clin Pract. 2019 Feb 5;6(3):227-234. doi: 10.1002/mdc3.12728. eCollection 2019 Mar.
Non-motor symptoms (NMS) are integral to Parkinson's disease (PD) and have a detrimental effect on patients and their caregivers. Clinical quantification has been aided by the development of comprehensive assessments such as the Non-Motor Symptoms Questionnaire (NMSQuest) and Scale (NMSS). The NMSS has been widely used in clinical studies and trials; however, since its validation in 2007, our understanding of NMS has changed substantially. With the support of the International Parkinson and Movement Disorder Society (IPMDS), after a detailed peer review an initiative to develop an updated version of NMSS, the MDS-NMS was launched in 2015.
This paper encapsulates the data from the pre-validation phases carried out under the auspices of the IPMDS Non-Motor PD Study Group.
Item selection and wording (formatted as a rater-based tool) were based on the NMSS, literature review, and expert consensus. Neurologists, PD patients, and healthy controls were included in the cognitive pretesting and administration of the preliminary version of the MDS-NMS. Primary data on acceptability and reliability were obtained.
The pilot study, carried out in English in the United Kingdom and the United States, demonstrated that the preliminary version of the MDS-NMS was comprehensive, understandable, and appropriate. Data quality was excellent; moderate floor effect was present in patients for most MDS-MNS domains, with some components showing weak internal consistency. The results led to additional instrument modifications.
Qualitative and quantitative research results have led to an updated NMSS, the definitive version of the MDS-NMS, which is currently being validated.
非运动症状(NMS)是帕金森病(PD)的重要组成部分,对患者及其照料者有不利影响。诸如非运动症状问卷(NMSQuest)和量表(NMSS)等综合评估工具的开发有助于临床量化。NMSS已在临床研究和试验中广泛使用;然而,自2007年其验证以来,我们对NMS的理解已发生了很大变化。在国际帕金森和运动障碍协会(IPMDS)的支持下,经过详细的同行评审,一项开发NMSS更新版本的计划于2015年启动,即多系统萎缩非运动症状量表(MDS-NMS)。
本文总结了在IPMDS非运动性帕金森病研究组主持下进行的预验证阶段的数据。
项目选择和措辞(格式化为基于评估者的工具)基于NMSS、文献综述和专家共识。神经科医生、PD患者和健康对照者被纳入MDS-NMS初步版本的认知预测试和施测。获得了关于可接受性和可靠性的原始数据。
在英国和美国以英语进行的试点研究表明,MDS-NMS初步版本全面、易懂且合适。数据质量极佳;大多数MDS-MNS领域的患者存在中度地板效应,一些组件显示出较弱的内部一致性。结果导致对该工具进行了额外修改。
定性和定量研究结果促成了NMSS的更新版本,即MDS-NMS的最终版本,目前正在进行验证。